Molipharma

MoliPharma is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapies for metabolic disorders, including obesity, type 2 diabetes, and MASH. The company leverages its deep expertise in incretin biology to develop multi-receptor agonists that target the GLP-1, GIP, and glucagon receptors. Its lead program, ML-001, is a triple agonist designed to provide superior weight loss and glycemic control compared to existing dual or single agonists. Based in Suzhou, China, MoliPharma is supported by leading venture capital investors and aims to address significant unmet needs in the global metabolic health market. The company's research efforts also extend to oral delivery technologies for peptide-based drugs.